CBD Oil for Sleep and Chronic Fatigue Syndrome: How CBD Addresses ME/CFS Sleep Disruption, Neuroinflammation, and Post-Exertional Malaise

By PureCraft Editorial Team | PureCraft CBD | Updated October 2026

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) presents one of the most complex and least understood sleep disruption profiles in clinical medicine. Despite profound, disabling fatigue — the defining symptom experienced by 100% of patients — ME/CFS produces non-restorative sleep rather than simply increased sleep need. Patients sleep adequate or even extended hours yet awaken feeling no more restored than before sleep; they experience debilitating daytime fatigue that is paradoxically worsened by rest in many cases; and polysomnographic studies consistently document a specific sleep architecture anomaly — alpha-delta sleep — in which alpha-wave intrusion during N3 slow-wave sleep degrades the restorative quality of deep sleep without reducing total sleep duration. This is the defining paradox of ME/CFS sleep: fatigue is profound but sleep does not resolve it, because the sleep itself is architecturally non-restorative in ways that standard sleep duration metrics completely miss.

CBD oil's mechanistic relevance to ME/CFS sleep is substantial — but requires understanding the disease's specific biology to appreciate why. ME/CFS is now understood as a neuroimmune condition: chronic neuroinflammation (microglial activation and elevated neuroinflammatory markers documented by PET imaging in ME/CFS patients), HPA axis dysfunction (cortisol hypo-responsiveness — the opposite of the HPA hyperactivation seen in most stress-related disorders), autonomic nervous system dysregulation (orthostatic intolerance, reduced heart rate variability, parasympathetic withdrawal), and mitochondrial energy metabolism dysfunction collectively produce the symptom profile of ME/CFS. CBD's CB2 neuroinflammatory mechanism, HPA modulatory mechanism, and ANS parasympathetic support mechanisms address multiple components of the ME/CFS neuroimmune pathology that drives sleep disruption — not as a cure for a poorly-understood condition, but as a mechanistically-grounded adjunct that addresses genuine pathological drivers of ME/CFS sleep dysfunction.

How ME/CFS Disrupts Sleep: The Five Core Mechanisms

1. Alpha-Delta Sleep Anomaly: The Defining ME/CFS Sleep Architecture Pathology

The alpha-delta sleep anomaly — also called alpha intrusion or alpha-wave intrusion into slow-wave sleep — is the polysomnographically documented hallmark of ME/CFS sleep architecture. In normal sleep, N3 (slow-wave sleep, delta sleep) is characterized by high-amplitude, low-frequency delta waves (0.5–4 Hz) with near-complete suppression of the alpha waves (8–12 Hz) associated with relaxed wakefulness. In alpha-delta sleep, alpha activity (8–12 Hz) intrudes into and co-occurs with delta waves during N3 — producing a hybrid EEG pattern in which delta waves are present (indicating N3 by standard scoring criteria) but alpha co-activation prevents the full thalamo-cortical de-arousal that N3 normally achieves. The subjective consequence is profound: the patient is technically "asleep" in N3 by EEG scoring, but the alpha co-activation maintains a partial arousal state that prevents the restorative physiological processes of N3 — growth hormone secretion, glymphatic CSF clearance, synaptic pruning, cellular energy restoration — from occurring at full efficiency. The patient wakes feeling unrestored despite a full night of technically "normal" sleep duration with apparent N3 stages present throughout.

The mechanism of alpha-delta sleep in ME/CFS: thalamo-cortical circuit dysregulation from neuroinflammation (microglial activation in thalamus and brainstem reticular formation disrupts the thalamic gating mechanism that normally suppresses alpha during N3), combined with hyperactive pain/sensory processing (alpha intrusion in slow-wave sleep is also the characteristic finding in fibromyalgia — conditions that overlap substantially with ME/CFS — where central sensitization maintains a sensory vigilance signal that prevents full thalamic de-arousal), and ANS dysregulation (parasympathetic withdrawal → heightened sympathetic tone → arousal signals that maintain partial cortical activation during attempted N3). The alpha-delta sleep anomaly is not a deficit in sleep drive — it is a failure of the neural gating mechanisms that should achieve full cortical de-arousal during N3, driven by the neuroinflammatory and autonomic dysregulation underlying ME/CFS.

2. Neuroinflammation: Microglial Activation as the Central Pathological Driver

PET imaging studies (Nakatomi et al. 2014, using [¹¹C]PK11195 TSPO radioligand for neuroinflammation) documented elevated microglial activation throughout the brain in ME/CFS patients — particularly in brainstem, thalamus, amygdala, and prefrontal cortex — regions central to sleep-wake regulation, autonomic control, and emotional processing. This central neuroinflammation (not peripheral autoimmunity, but CNS-resident microglial and astrocytic inflammatory activation) is the proposed pathological substrate for multiple ME/CFS symptoms simultaneously: the cognitive dysfunction ("brain fog"), the post-exertional malaise, the autonomic dysregulation, and the sleep architecture anomaly. The thalamic neuroinflammation is particularly relevant to the alpha-delta sleep anomaly: thalamic relay neurons are the gating mechanism that suppresses alpha during N3, and microglial-driven inflammatory disruption of thalamic circuitry directly impairs the alpha-suppression that N3 requires. The brainstem neuroinflammation disrupts the ascending arousal systems (locus coeruleus, raphe nuclei, basal forebrain cholinergic projections) that modulate the sleep-wake cycle — producing the irregular sleep-wake rhythm, sleep-onset difficulty, and post-awakening non-restoration characteristic of ME/CFS.

3. HPA Axis Hypo-Responsiveness: The Opposite of Typical Stress Dysregulation

ME/CFS produces a distinctive HPA axis pattern that is the inverse of the HPA hyperactivation seen in most stress-related disorders. Rather than elevated cortisol (the chronic stress/anxiety pattern), ME/CFS characteristically shows hypocortisolism — blunted cortisol awakening response (CAR), reduced 24-hour cortisol output, blunted ACTH responses to CRH stimulation, and evidence of central HPA axis hypo-responsiveness. The cortisol awakening response (CAR) — the 50–100% cortisol rise in the first 30–45 minutes after waking that normally promotes alertness, mobilizes energy, and prepares the immune system for daily activity — is significantly blunted in ME/CFS, contributing to the characteristically unrefreshing morning awakening (not enough cortisol to drive morning arousal and energy mobilization) and the profound post-waking fatigue that is more disabling than the fatigue during sleep itself. The hypocortisolism of ME/CFS also has secondary immune consequences: cortisol is normally anti-inflammatory, and its deficiency in ME/CFS may contribute to the persistence of the neuroinflammatory microglial activation by removing a key anti-inflammatory regulatory signal. The sleep-specific consequences of ME/CFS HPA hypo-responsiveness: blunted morning CAR → non-restorative morning awakening; insufficient daytime cortisol → inadequate daytime arousal → further sleep-wake rhythm dysregulation; and the loss of cortisol's anti-inflammatory role → perpetuation of the neuroinflammation driving sleep architecture disruption.

4. Autonomic Nervous System Dysregulation and Orthostatic Intolerance

Autonomic nervous system (ANS) dysregulation is present in the majority of ME/CFS patients — with reduced heart rate variability (HRV), sympathetic predominance, reduced parasympathetic (vagal) tone, and orthostatic intolerance (symptoms worsening upon standing, with documented postural tachycardia syndrome [POTS] in a substantial ME/CFS subset). The ANS dysregulation directly affects sleep through two mechanisms. First, the sympathetic predominance and reduced vagal tone maintain a heightened arousal state that prevents the parasympathetic shift required for sleep onset and N3 deepening — the same mechanism by which chronic stress disrupts sleep, but originating from autonomic dysregulation rather than psychological hyperarousal. Second, the orthostatic intolerance of ME/CFS produces a paradoxical phenomenon: supine rest (lying down for sleep) should reduce the orthostatic stress, but many ME/CFS patients with significant dysautonomia report worsening of some symptoms or failure to feel genuinely rested in the supine sleep position — possibly because the cardiovascular regulation required to maintain adequate cerebral perfusion in different body positions continues to demand autonomic effort during sleep in dysautonomic patients. Nocturnal heart rate variability (HRV) is significantly reduced in ME/CFS, confirming that the ANS dysregulation persists through the sleep period rather than normalizing during sleep.

5. Post-Exertional Malaise and the Sleep-Exertion Vicious Cycle

Post-exertional malaise (PEM) — the pathological worsening of all ME/CFS symptoms (including sleep disruption) following physical, cognitive, or emotional exertion — creates a sleep-specific vicious cycle. Even minimal exertion (a short walk, a conversation, reading for 30 minutes) can trigger PEM in moderate-to-severe ME/CFS, producing 24–72-hour (sometimes longer) delayed worsening of fatigue, pain, cognitive dysfunction, and sleep disruption. The mechanism of PEM is not fully established but likely involves: failure of mitochondrial oxidative phosphorylation under metabolic demand (lactate accumulation even from minimal exercise); neuroinflammatory escalation triggered by physical stress; ANS dysregulation amplification; and immune activation producing cytokine-mediated N3 suppression. The sleep-exertion cycle: PEM-triggered neuroinflammatory activation further disrupts N3 → deeper non-restorative sleep → worse fatigue → lower exertion threshold for subsequent PEM → more frequent PEM triggers from activities of daily living → cumulative sleep disruption worsening. This cycle is the reason the energy envelope management strategy (pacing — staying strictly within the energy envelope to avoid PEM triggers) is the primary behavioral management for ME/CFS, and why any intervention that reduces neuroinflammation and improves sleep architecture could theoretically raise the PEM threshold.

ME/CFS Sleep Disruption: Mechanism Summary

CBD Oil's Mechanisms for ME/CFS Sleep: Why CB2 Neuroinflammation Is the Primary Target

CB2 Microglial Modulation and Thalamic Sleep Architecture Restoration

The PET-documented thalamic microglial activation of ME/CFS is the most directly sleep-relevant neuroinflammatory finding — thalamic neurons are the gating mechanism for alpha-wave suppression during N3, and their disruption by microglial inflammatory activation is the proposed mechanism of the alpha-delta sleep anomaly. CBD's CB2 mechanism — promoting microglial M1→M2 transition and suppressing NF-κB-driven neuroinflammatory cytokine production — is directly applicable to this thalamic microglial activation. By reducing the thalamic neuroinflammatory environment, CBD's CB2 mechanism may partially restore the thalamic gating function that alpha-delta sleep anomaly represents as dysfunctional. This is not an established clinical finding for CBD in ME/CFS (no dedicated CBD-ME/CFS trials have been published) — it is a mechanistically grounded hypothesis based on the known biology of CB2 microglial modulation and the documented thalamic neuroinflammation of ME/CFS. The same reasoning applies to brainstem neuroinflammation: CB2-mediated reduction of brainstem reticular formation microglial activation may support more regular ascending arousal system function, contributing to more consistent sleep-wake rhythm maintenance that ME/CFS patients characteristically lose.

The timeline implication is important and different from most sleep conditions: because the alpha-delta sleep anomaly is driven by structural neuroinflammatory disruption of thalamic circuits rather than acute HPA or adenosine dysregulation, the CB2 neuroinflammatory mechanism will be the most relevant but slowest mechanism to produce sleep improvement. Expect 12–16 weeks of consistent daily CBD at therapeutic dose for meaningful CB2-mediated neuroinflammatory attenuation to accumulate at the thalamic level. This extended timeline is appropriate to ME/CFS's nature as a chronic neuroimmune condition with months-to-years of accumulated neuroinflammatory burden — it does not resolve in 4–8 weeks. The HPA and adenosine/CB1 mechanisms may provide earlier symptomatic improvement in sleep quality ratings before the CB2 neuroinflammatory mechanism achieves its full contribution.

The HPA Nuance in ME/CFS: CBD in Hypocortisolism Context

The HPA dysregulation of ME/CFS is the inverse of the HPA hyperactivation pattern that CBD's HPA normalization mechanism most directly addresses. In most sleep disorders (chronic stress insomnia, anxiety-driven insomnia, PTSD), the problem is too much cortisol — and CBD's CB1/5-HT1A suppression of CRH and cortisol output is beneficially normalizing. In ME/CFS, the problem is too little cortisol output — particularly the blunted cortisol awakening response (CAR). The question is whether CBD's HPA mechanism is bidirectionally normalizing or purely suppressive: the endocannabinoid system's role in HPA regulation is complex — ECS activation suppresses HPA axis reactivity to stressors, but the baseline HPA tone reflects a different regulatory balance. Preclinical evidence suggests ECS modulation supports HPA homeostasis rather than simply suppressing cortisol output in all contexts — in hypocortisolic states, CB1 modulation may support the HPA responsiveness needed to normalize CAR. The 5-HT1A mechanism may support cortisol awakening response amplitude through serotonin's role in morning arousal regulation. The honest position: CBD's HPA mechanism in ME/CFS is more uncertain than in stress-driven HPA hyperactivation disorders, and ME/CFS patients should monitor morning energy and post-awakening functional capacity as specific indicators of whether CBD's HPA effect is beneficial or counterproductive for their individual HPA pattern.

ANS Parasympathetic Support and HRV Improvement

Multiple clinical studies have documented CBD's effect on autonomic nervous system balance — specifically increased parasympathetic (vagal) tone and improved heart rate variability (HRV) following CBD administration. The mechanism: CBD's 5-HT1A activation suppresses the locus coeruleus noradrenergic system (the primary sympathetic arousal driver), reducing sympathetic dominance; CB1 activation in the hypothalamic autonomic regulatory centers modulates the sympatho-vagal balance toward parasympathetic predominance; and FAAH-elevated anandamide has direct vagal potentiating effects. For ME/CFS patients with documented ANS dysregulation and reduced HRV: CBD's parasympathetic-promoting mechanism directly addresses the autonomic substrate of both sleep-onset difficulty (parasympathetic shift required for sleep initiation is impaired by sympathetic dominance) and the persistence of autonomic dysregulation through the sleep period (reduced HRV during sleep). Improvement in nocturnal HRV — a measurable, objective metric that many ME/CFS patients now track with consumer wearables — may serve as an early indicator that CBD's ANS mechanism is providing benefit before subjective sleep quality improvements are apparent. ME/CFS patients with POTS should note that CBD's blood pressure and autonomic effects are modest — CBD is not a treatment for POTS (which requires orthostatic management strategies including fluid/salt loading, compression, beta-blockers, or fludrocortisone under physician supervision), but its vagal-promoting mechanism may modestly reduce the sympathetic overdrive component of POTS-associated dysautonomia.

Adenosine and the ME/CFS Sleep Pressure Anomaly

ME/CFS presents a paradox in the two-process sleep model: Process S (homeostatic sleep pressure, driven by adenosine accumulation during wakefulness) should be enormous given ME/CFS patients' profound fatigue — yet they do not achieve proportionally deep or restorative N3 despite apparently high sleep pressure. This suggests either that adenosine accumulation is abnormal in ME/CFS (possibly from mitochondrial energy metabolism dysfunction that alters adenosine production from ATP), or that the thalamo-cortical systems that translate sleep pressure into N3 are functionally disrupted (consistent with the alpha-delta anomaly from thalamic neuroinflammation). CBD's adenosine mechanism (ENT1 blockade → elevated extracellular adenosine → A1/A2A receptor activation → N3 propensity amplification) may help by enhancing the adenosine signal's translation into actual N3 architecture — amplifying whatever sleep pressure is generated to produce deeper N3 more reliably, even when the thalamic gating dysfunction from neuroinflammation is still being addressed by the longer-timeline CB2 mechanism. Think of CBD's adenosine mechanism as supporting the downstream sleep architecture translation while CB2 neuroinflammation reduction addresses the upstream thalamic gating impairment driving the alpha-delta anomaly.

ME/CFS and Fibromyalgia Overlap: Clinical Comorbidity and Shared Mechanisms

Long COVID ME/CFS and CBD: Emerging Relevance

Long COVID — defined as symptoms persisting or newly appearing 4+ weeks after SARS-CoV-2 infection — produces ME/CFS-like presentations in a substantial proportion of cases, with fatigue, cognitive impairment ("brain fog"), post-exertional malaise, and non-restorative sleep among the most common and disabling Long COVID symptoms. The neuroinflammatory basis of Long COVID ME/CFS is increasingly established: SARS-CoV-2 neuroinvasion, neuroinflammation from CNS ACE2 expression and immune dysregulation, microglial activation (documented in Long COVID brain imaging studies), and autonomic nervous system dysfunction (documented orthostatic intolerance in Long COVID) parallel the ME/CFS neurobiology closely.

CBD's mechanistic relevance to Long COVID sleep disruption follows the same logic as classic ME/CFS: CB2 microglial modulation for SARS-CoV-2-triggered neuroinflammation, ANS parasympathetic support for Long COVID dysautonomia, adenosine for N3 architecture support in the context of non-restorative sleep, and 5-HT1A for the anxiety and mood disruption commonly associated with Long COVID. The mitochondrial energy metabolism dysfunction documented in Long COVID (SARS-CoV-2 impacts mitochondrial function through multiple mechanisms) aligns with the ME/CFS mitochondrial mechanism discussion. Honest caveat: Long COVID research is rapidly evolving and the specific evidence for CBD in Long COVID is limited; the mechanistic parallels with ME/CFS provide the strongest basis for extrapolation. Long COVID patients should consult their treating physician and may benefit from Long COVID clinic programs that provide comprehensive multi-system evaluation.

Evidence for CBD in ME/CFS Sleep

Specific clinical trial evidence for CBD in ME/CFS sleep is absent — no dedicated CBD-ME/CFS RCTs have been published as of this writing. ME/CFS clinical trial infrastructure has historically been underfunded relative to the condition's burden. However, mechanistically relevant evidence includes: the CB2 microglial mechanism is supported by preclinical neuroinflammation studies; the ANS vagal-promoting effect of CBD has been documented in human studies of HRV; the alpha-delta sleep anomaly of fibromyalgia (the closest-studied overlap condition) is the mechanism for which CBD's CB1/adenosine N3-deepening effect is most relevant; and the foundational CBD sleep literature (Shannon et al. 2019) included patients with anxiety and sleep complaints across a range of presentations without excluding ME/CFS-type profiles.

Honest assessment: ME/CFS is a condition where CBD's mechanistic case is compelling but clinical evidence is nearly absent. The condition is severely undertreated and underresearched; patients often have no good pharmacological options for the sleep disruption specifically; and the CB2 neuroinflammatory, ANS parasympathetic, and adenosine mechanisms address genuine ME/CFS pathology rather than just sedating over symptoms. The expected effect for ME/CFS patients is likely more modest than for conditions with clearer sleep-mechanism matches, will require more consistent long-term use (12–16+ weeks), and should be framed as one component of a comprehensive ME/CFS management strategy rather than a standalone sleep solution. Setting realistic expectations — partial improvement in sleep quality ratings, potential HRV improvement as an objective marker, possible reduction in morning non-restoration severity — is appropriate for this population.

Medication Interactions: ME/CFS Medications and CBD

Dosing CBD Oil for ME/CFS Sleep Disruption

PureCraft Products for ME/CFS Sleep

Foundation: Nanoemulsion Precision for Sensitive Titration

Nano CBD Broad Spectrum Oil — The sublingual nanoemulsion oil is essential for ME/CFS-specific reasons beyond its general sleep advantages. ME/CFS patients require the most precise dose titration available — chemical sensitivity in ME/CFS means some patients need to begin at 5–10 mg and increase in 2.5–5 mg increments; the sublingual oil's drop-by-drop control provides this precision. The nanoemulsion's consistent bioavailability is particularly important for the CB2 neuroinflammatory mechanism: maintaining consistent plasma CBD levels for sustained CB2 engagement requires predictable absorption, and standard CBD oil's highly variable 6–19% bioavailability produces plasma level fluctuations that may prevent the sustained CB2 signal needed for thalamic microglial modulation. Broad spectrum provides beta-caryophyllene (CB2 agonist terpene — additive CB2 neuroinflammatory mechanism) and the full entourage terpene anti-inflammatory complement that may compound CBD's neuroinflammatory mechanism at a level important for the ME/CFS neuroinflammatory burden. Take 30 minutes before intended sleep, starting at 10–15 mg and titrating toward 25–40 mg over 4–8 weeks, monitoring for paradoxical stimulation or PEM triggers from each dose increment.

Extended Overnight N3 Support

Nano CBD Water-Soluble Broad Spectrum Softgels — ME/CFS patients characteristically have non-restorative sleep throughout the night — not just at sleep onset or in specific awakening episodes — because the alpha-delta anomaly affects N3 quality throughout the sleep period. The softgel taken at bedtime (30–45 minutes after the evening oil, once oil dosing is established) provides extended-release CBD coverage across the full sleep period, maintaining CB2 microglial engagement and CB1/adenosine N3-deepening effect through the multiple N3 cycles of the night. The sustained overnight profile addresses the alpha-delta anomaly more comprehensively than the sublingual oil's shorter peak duration — the thalamic gating mechanism requires consistent CB2/CB1 engagement across the full sleep period rather than just the first 2–3 hours when sublingual oil is at peak plasma levels. For ME/CFS patients with significant early-morning non-restoration (waking after 7–8 hours still feeling profoundly unrestored), the bedtime softgel's overnight coverage is particularly relevant. Add only after the evening oil dose is fully established and tolerated, starting at a modest dose (one softgel) to monitor response.

Daytime Neuroinflammation Management Within the Energy Envelope

Nano CBD Infused Vegan Broad Spectrum Gummies — For ME/CFS patients who can tolerate a daytime dose without excessive sedation or ANS effects, a morning or mid-day broad spectrum gummy (10 mg, starting low) extends CB2 neuroinflammatory engagement through the daytime period — consistent with the principle that chronic neuroinflammation requires sustained CB2 signal across the full day rather than only during the sleep period. The daytime gummy also addresses the ME/CFS pain and cognitive symptom dimensions: CB2 and TRPV1 mechanisms for any pain component (particularly relevant for ME/CFS-FM overlap patients); and modest ANS vagal support during the daytime period when orthostatic symptoms are most prominent. Critical caveat for ME/CFS: the energy envelope pacing principle applies to CBD as to all activities — some ME/CFS patients with severe chemical sensitivity or HPA sensitivity may find the daytime gummy produces unacceptable sedation or ANS effects within their limited tolerance. The evening oil is the priority; the daytime gummy is secondary and should be introduced only after evening dosing is stable, well-tolerated, and showing initial benefit signs. Start at the lowest available dose increment.

When N3 Architecture Support Is the Primary Goal

Nano CBD CBN D9 Infused Vegan Gummies with Melatonin — For ME/CFS patients who are not drug-tested and have established a stable, well-tolerated CBD regimen through oil titration (establishing that CBD is not producing paradoxical stimulation or symptom worsening at therapeutic dose), this combination product addresses multiple ME/CFS sleep mechanisms simultaneously. CBN's GABA-A/GABA-B and CB1 activity provides additional thalamo-cortical sedation that specifically targets the alpha-wave intrusion of the alpha-delta anomaly — GABA-mediated thalamic inhibition reduces the alpha-wave breakthrough that degrades N3 quality. Melatonin addresses the circadian dimension of ME/CFS sleep dysregulation — the irregular sleep-wake rhythm driven by brainstem neuroinflammation compromises melatonin's circadian signal, and supplemental melatonin helps anchor the sleep window with a clear MT1/MT2 signal. D9 THC provides CB1 activation that contributes additional sleep-state stabilization. The combination is theoretically well-matched to ME/CFS's alpha-delta anomaly specifically — GABA-mediated thalamic alpha suppression (CBN/THC) plus adenosine/CB1 N3-deepening (CBD) plus circadian anchoring (melatonin) addresses the alpha-delta mechanism from three complementary angles. This is the maintenance-phase product for ME/CFS patients who have completed 12+ weeks of oil titration and established tolerability. The product should not be the starting point — the conservative titration protocol applies to ME/CFS above all conditions in this series.

Frequently Asked Questions About CBD Oil for Sleep and ME/CFS

Related Articles

• → CBD Oil for Sleep and Fibromyalgia: Alpha-Delta Sleep, Central Sensitization, and ECS Deficiency
• → CBD Oil for Sleep and Autoimmune Disease: CB2 Immunomodulation and Cytokine-Driven Sleep Disruption
• → CBD Oil for Deep Sleep: N3 Slow-Wave Sleep, GH Secretion, and the Glymphatic System
• → CBD Oil for Sleep and Anxiety: HPA Axis, 5-HT1A, and Hyperarousal-Driven Insomnia
• → CBD Oil for Sleep and Chronic Pain: TRPV1, Descending Inhibition, and the Pain-Sleep Cycle

References

1. Blessing EM, et al. Cannabidiol as a Potential Treatment for Anxiety Disorders. Neurotherapeutics. 2015;12(4):825–836. PMID: 26341731
2. Shannon S, et al. Cannabidiol in Anxiety and Sleep: A Large Case Series. Perm J. 2019;23:18–041. PMID: 30624194
3. Russo EB. Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manag. 2016;4(1):245–259. PMID: 28861491
4. Crippa JA, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder. J Psychopharmacol. 2011;25(1):121–130. PMID: 20829306
5. Corroon J, Phillips JA. A Cross-Sectional Study of Cannabidiol Users. Cannabis Cannabinoid Res. 2018;3(1):152–161. PMID: 30014049
6. Capano A, et al. Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients. Postgrad Med. 2020;132(1):56–61. PMID: 31711352